Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services;
H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services;
S. 3558, a bill to prohibit contracting with certain biotechnology providers;
H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.
Duration: February 1, 2018
to
present
General Issues: Health Issues , Taxation/Internal Revenue Code , Transportation , Trade (Domestic & Foreign) , Defense , Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Alcohol & Drug Abuse , Food Industry (Safety, Labeling, etc.)
Spending: about $10,350,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, U.S. Trade Representative (USTR), Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 16.
Original Filing: 301550821.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services;
H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services;
S. 3558, a bill to prohibit contracting with certain biotechnology providers;
H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Jan. 16.
Original Filing: 301525059.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and Section 502 of H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
The Fiscal Year 2024 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the U.S. Preventive Services Task Force; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 866, the American Innovation and Jobs Act, and H.R. 2673, the American Innovation and R & D Competitiveness Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
Laboratory Corporation of America Holdings amended a lobbying report for in-house lobbying in Q32023 on Oct. 24, 2023
Original Filing: 301517500.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
S. 2333, the Pandemic and All-Hazards Prevention and Response Act, Section 204, provisions relating to a pilot program for public health data availability;
H.R. 3791, the Improving DATA in Public Health Act, Section 107 of H.R. 4420, the Preparedness and Response Authorization Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories;
S. 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act, provisions relating to medical debt;
H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
The Fiscal Year 2024 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the U.S. Preventive Services Task Force; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Oct. 13, 2023.
Original Filing: 301500315.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
S. 2333, the Pandemic and All-Hazards Prevention and Response Act, Section 204, provisions relating to a pilot program for public health data availability;
H.R. 3791, the Improving DATA in Public Health Act, Section 107 of H.R. 4420, the Preparedness and Response Authorization Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories;
S. 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act, provisions relating to medical debt;
H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
The Fiscal Year 2024 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the U.S. Preventive Services Task Force; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on July 13, 2023.
Original Filing: 301475776.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 3791, the Improving DATA in Public Health Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories;
H.R. 3795, the Diagnostic Testing Preparedness Plan Act, and H.R. 3840, the Ensuring Sufficient Supply of Testing Act, provisions relating to laboratory testing capabilities in connection with reauthorization of the Pandemics and All-Hazards Preparedness Act;
H.R. 3248, the Diagnostic Lab Testing Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services;
The Patent Eligibility Restoration Act of 2023, provisions relating to patent subject matter eligibility;
The American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy;
Federal policy related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI);
Federal policy related to oversight of artificial intelligence; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 14, 2023.
Original Filing: 301451854.xml
Lobbying Issues
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
The CONNECT for Health Act, provisions relating to Medicare coverage of telehealth services and limitations on payment for certain laboratory tests;
The American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy;
Federal policy related to implementation of Section 2213(d) of the Consolidated Appropriations Act, 2023, P.L. 117-328, and Section 18115(a) of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to demographic data reporting obligations for laboratories and reauthorization of the Pandemics and All-Hazards Preparedness Act;
S. 866, the American Innovation and Jobs Act, provisions relating to deductibility of research and development expenses for corporate income tax purposes under Internal Revenue Code Section 174;
The Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; and
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301432778.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests;
H.R. 4040, the Advancing Telehealth Beyond COVID-19 Act, H.R. 6202, the Telehealth Extension Act, and H.R. 7573/S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests;
H.R. 8152, the American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy;
S. 3799, the PREVENT Pandemics Act, provisions relating to demographic data reporting obligations for laboratories;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research;
H.R.3173/S. 3018, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of health care services;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development;
Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and
Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Oct. 18, 2022.
Original Filing: 301407223.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests;
H.R. 4040, the Advancing Telehealth Beyond COVID-19 Act, H.R. 6202, the Telehealth Extension Act, and H.R. 7573/S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests;
H.R. 8152, the American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy;
S. 3799, the PREVENT Pandemics Act, provisions relating to demographic data reporting obligations for laboratories;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research;
H.R. 8693, the No Cost for Monkeypox Testing Act, provisions relating to third party payer coverage of monkeypox testing;
S. 4734, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and
Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on July 18, 2022.
Original Filing: 301382465.xml
Lobbying Issues
Specific Issue Descriptions:
Healthcare issues related to clinical laboratories;
H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests;
H.R. 6202, the Telehealth Extension Act, and H.R. 7573/S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests;
H.R. 8152, the American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy;
S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories;
H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing;
H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information;
H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and
Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federal policy, and potential solutions, relating to supply chain disruptions resulting from Chinas implementation of sanitary and phytosanitary (SPS) measures in violation of the U.S.-China Phase One Deal and Chinas World Trade Organization obligations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 11, 2022.
Original Filing: 301344576.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
H.R. 6202, the Telehealth Extension Act, and S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests;
S. 3534, the Tracking Pathogens Act, provisions relating to genomic sequencing of variants of the SARS-CoV-2 virus;
S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories;
Federal policy related to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding;
H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;
H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing;
H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and
H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information;
H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research; and
Federal policy relating to CDC funding for standardization of pediatric reference range intervals and laboratory result harmonization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federal policy, and potential solutions, relating to supply chain disruptions resulting from Chinas implementation of sanitary and phytosanitary (SPS) measures in violation of the U.S.-China Phase One Deal and Chinas World Trade Organization obligations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Jan. 18, 2022.
Original Filing: 301325686.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
S. 610, the Protecting Medicare and American Farmers from Sequester Cuts Act, provisions relating to delays in data collection and rate changes pertinent to the Medicare Clinical Laboratory Fee Schedule, mitigation of the Medicare sequester and rate changes pertinent to the Medicare Physician Fee Schedule, and suspension of certain statutory pay-as-you-go requirements;
S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests;
H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing;
S. 1605, the National Defense Authorization Act for Fiscal Year 2022, provisions relating to TRICARE coverage of preconception and prenatal carrier screening;
H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and
Federal policy relating to use of pharmacogenetic information, including a discussion draft of the Right Drug Dose Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, provisions relating to cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federal policy, and potential solutions, relating to supply chain disruptions resulting from Chinas implementation of sanitary and phytosanitary (SPS) measures in violation of the U.S.-China Phase One Deal and Chinas World Trade Organization obligations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Oct. 15, 2021.
Original Filing: 301300136.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
H.R. 1868, provisions relating to extension of the Medicare sequester moratorium and waiver of certain statutory pay-as-you-go requirements;
S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests;
H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; and
Federal policy relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing, including a discussion draft of the Cures 2.0 Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federal policy, and potential solutions, relating to supply chain disruptions resulting from Chinas implementation of sanitary and phytosanitary (SPS) measures in violation of the U.S.-China Phase One Deal and Chinas World Trade Organization obligations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Federal policy relating to international tax reform
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
Laboratory Corporation of America Holdings amended a lobbying report for in-house lobbying in Q22021 on Oct. 15, 2021
Original Filing: 301300138.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
H.R. 1868, provisions relating to extension of the Medicare sequester moratorium and waiver of certain statutory pay-as-you-go requirements;
H.R. 1848, the LIFT America Act, provisions relating to funding of public health infrastructure and public health reporting;
S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests;
H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;
S. 1744, the Genomic Data Security Act, provisions relating to certification of laboratories under the Clinical Laboratory Improvement Amendments of 1988, Pub. L. 100-578;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
Federal policy relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing, including a discussion draft of the Cures 2.0 Act;
Federal policy relating to Medicare coverage of genetic and genomic testing and related services, including a discussion draft of the Advancing Access to Precision Medicine Act; and
Federal policy relating to CDC funding for public health surveillance and harmonizing lab results in the Fiscal Year 2022 Labor-HHS appropriations bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301282398.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
H.R. 1868, provisions relating to extension of the Medicare sequester moratorium and waiver of certain statutory pay-as-you-go requirements;
H.R. 1848, the LIFT America Act, provisions relating to funding of public health infrastructure and public health reporting;
S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests;
H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;
S. 1744, the Genomic Data Security Act, provisions relating to certification of laboratories under the Clinical Laboratory Improvement Amendments of 1988, Pub. L. 100-578;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
Federal policy relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing, including a discussion draft of the Cures 2.0 Act;
Federal policy relating to Medicare coverage of genetic and genomic testing and related services, including a discussion draft of the Advancing Access to Precision Medicine Act; and
Federal policy relating to CDC funding for public health surveillance and harmonizing lab results in the Fiscal Year 2022 Labor-HHS appropriations bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 19, 2021.
Original Filing: 301257765.xml
Lobbying Issues
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
H.R. 791 / S. 236, the Tracking COVID-19 Variants Act, provisions relating to funding COVID-19 surveillance and transmission studies using next generation sequencing;
H.R. 1319, Pub. L. 117-2, the American Rescue Plan Act of 2021, provisions relating to funding for genomic sequencing for SARS-CoV-2 variants and diagnostic testing for COVID-19;
H.R. 1946, the Medicare Multi-Cancer Detection Screening Coverage Act, provisions relating to Medicare coverage of multi-cancer screening tests;
H.R. 1868, provisions relating to extension of the Medicare sequester moratorium and waiver of certain statutory pay-as-you-go requirements;
H.R. 1848, the LIFT America Act, provisions relating to funding of public health infrastructure and public health reporting;
S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests;
Federal policy relating to coverage of genetic counselor services in a draft of the Rare Cancer Awareness, Research and Treatment Act;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
Federal policy relating to drug development, including potential legislation known as Cures 2.0; and
Federal policy relating to CDC funding for harmonizing lab results in the Fiscal Year 2022 Labor-HHS appropriations bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Jan. 19, 2021.
Original Filing: 301236078.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
H.R. 8406, the HEROES Act, provisions in Section 307 relating to coverage of COVID-19 testing
H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time;
Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation;
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill;
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill; and
H. R. 133, the Consolidated Appropriations Act of 2021, provisions in Title I of Division BB relating to surprise billing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of cargo transport requirements codified at statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Oct. 9, 2020.
Original Filing: 301208507.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;
H.R. 7179, The Pandemic Liability Protection Act, H.R. 7059, the Coronavirus Provider Protection Act, and H.R. 7528, the Get America Back to Work Act, provisions relating to limitation of liability for COVID-19 related services;
H.R. 7615/S.4214, the Healthy Workplace Tax Credit Act, and H.R. 7658, the Workplace Testing Tax Credit Act, provisions relating to employer tax credits for back-to-work COVID-19 testing;
The Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act (Draft bill), and Section 109 of S. 4322, the Safely Back to School and Back to Work Act, provisions relating to requiring informed consent for secondary uses of human genetic information obtained through COVID-19 testing;
Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing;
H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time;
Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation;
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on July 10, 2020.
Original Filing: 301186730.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 266, the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federal policy relating to DOT implementation of cargo transport provisions codified in 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3593, the FORWARD Act, provisions relating to research and development tax credits.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 8, 2020.
Original Filing: 301154522.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 6201, the Families First Coronavirus Response Act, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, funding for child care for laboratory personnel, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;
S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests;
Federal policy relating to drug development;
Federal policy relating to implementation of anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential inclusion in the Fiscal Year 2021 Labor-HHS appropriations bill; and
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential inclusion in the Fiscal Year 2021 Agriculture-FDA appropriations bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, provisions relating to deferral of employer payroll taxes.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2019
In Q4, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Jan. 9, 2020.
Original Filing: 301104102.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act;
H.R. 3584/ S. 3049, the Laboratory Access for Beneficiaries (LAB) Act, provisions relating to modification of reporting of private-sector payments used to establish Medicare rates for clinical diagnostic laboratory tests and directing a third party study and report including recommendations on private-sector payment data collection requirements and Medicare rate methodologies.
H.R. 1865, the Further Consolidated Appropriations Act, Section 105 of Division N, provisions incorporating the LAB Act;
H.R. 3235, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counseling services, and S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests;
Cures 2.0, potential legislative initiative (Reps. Upton and DeGette);
Federal policy relating to drug development;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220);
Federal policy relating to subject matter eligibility for patents of laboratory tests; and
H.R. 3630, the No Surprises Act, H.R. 2328, the Reauthorizing and Extending Americas Community Health (REACH) Act, and S. 1895, the Lower Health Care Costs Act, provisions relating to surprise medical billing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 748/S. 684, the Middle Class Health Benefits Tax Repeal Act, provisions relating to taxation of health insurance benefits.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Oct. 17, 2019.
Original Filing: 301068113.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act;
H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act, H.R. 3235, the Access to Genetic Counselor Services Act, and S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare, Medicaid and TRICARE coverage and reimbursement for laboratory services and reforms to the Clinical Laboratory Fee Schedule;
Federal policy relating to drug development;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220);
Federal policy relating to subject matter eligibility for patents of laboratory tests; and
H.R. 3630, the No Surprises Act, H.R. 2328, the Reauthorizing and Extending Americas Community Health (REACH) Act, and S. 1895, the Lower Health Care Costs Act, provisions relating to surprise medical billing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of DOT statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, regarding cargo transport.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on July 19, 2019.
Original Filing: 301051069.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act;
H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act, and H.R. 2009, the Removing Barriers to Allergy Diagnostic Testing Act, provisions relating to Medicare, Medicaid, and TRICARE coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule;
Federal policy relating to drug development;
Federal policy relating to the implementation of anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220);
Federal policy relating to subject matter eligibility for patents of laboratory tests;
H.R. 2143, the Promoting Integrity in Medicine Act, provisions relating to physician self-referral;
S. 684, the Middle Class Health Benefits Tax Repeal Act, provisions relating to the taxation of employer-sponsored health care coverage; and
H.R. 3630, the No Surprises Act, H.R. 3502, the Protecting People from Surprise Medical Bills Act, S. 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act, and S. 1895, the Lower Health Care Costs Act, provisions relating to surprise medical billing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of DOT statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, regarding cargo transport; federal policy relating to the master file system used by the U.S. Fish and Wildlife Service to streamline permitting for the routine transportation of biological samples.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2968, the Department of Defense Appropriations Act, provisions relating to the development of platelet and plasma products for the treatment of traumatic bleeding.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 11, 2019.
Original Filing: 301024460.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare and TRICARE coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development; federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); and federal policy relating to subject matter eligibility for patents of laboratory tests.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of DOT statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, regarding cargo transport.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2020 Defense Appropriations bill, provisions relating to the development of platelet and plasma products for the treatment of traumatic bleeding.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Jan. 16, 2019.
Original Filing: 301005148.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA), FDAs technical assistance on DAIA, and the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development; federal policy relating to surprise medical bills, including the discussion draft of the Protecting Patients from Surprise Medical Billing Act; and H.R. 7083, the Access to Genetic Counselor Services Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of DOT statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, regarding cargo transport.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on Oct. 8, 2018.
Original Filing: 300983396.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) and FDAs technical assistance on DAIA; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development; federal policy relating to appropriating funds for the National Evaluation System for health Technology Coordinating Center (NESTcc); federal policy relating to surprise medical bills, including the discussion draft of the Protecting Patients from Surprise Medical Billing Act, and H.R. 6470 / S. 3158, federal policy relating to appropriating funds for HHS for FY 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federal policy related to possible DOT actions regarding cargo transport.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on July 16, 2018.
Original Filing: 300965395.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA); Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development; and federal policy relating to appropriating funds for the National Evaluation System for health Technology Coordinating Center (NESTcc).
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Laboratory Corporation of America Holdings had in-house lobbyists. The report was filed on April 12, 2018.
Original Filing: 300944347.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA); Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; and federal policy relating to drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
DOT regulations regarding cargo transport
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
Laboratory Corporation of America Holdings filed a lobbying registration on March 9, 2018 for in-house lobbying efforts, effective Feb. 1, 2018.
Original Filing: 300941312.xml
Issue(s) they said they’d lobby about: Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA); Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; TRICARE; issues related to forensic DNA testing and occupational drug testing; issues related to food safety and nutritional analysis; and federal policy relating to drug development. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...